LEGO® Education and FIRST® Inspire STEAM Learning with New Architecture-Themed LEGO sets for 2019-2020 FIRST® LEGO® League Season
Today at the FIRST® Championship, LEGO® Education and FIRST unveiled two new, exclusive LEGO sets created specifically for the 2019-2020 FIRST® LEGO® League Jr. and FIRST® LEGO® League season. LEGO Education also announced today that its newly released LEGO Education SPIKE™ Prime with the new SPIKE™ Prime Competition Expansion Set can be used along with LEGO® MINDSTORMS® Education EV3 in FIRST LEGO League. LEGO Education SPIKE Prime and the SPIKE Prime Expansion Set can be pre-ordered today in the U.S. and will be available around the world in August 2019.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190417005754/en/
FIRST® LEGO® League CITY SHAPER Challenge Set (Photo: Business Wire)
FIRST, an international youth not-for-profit, and LEGO teamed up in 1998 to create FIRST LEGO League and FIRST LEGO League Jr. with the goal to give students around the world from 6 to 16 years old* a team-oriented in-school and afterschool activity to build confidence and friendly-competition spirit while also learning STEAM skills. Through its partnership with FIRST, LEGO Education is not only committed to helping every student build STEAM skills but also to build confidence through hands-on learning and team collaboration.
“If you meet students where they are, challenge them appropriately, allow them meaningful failures, they will ultimately succeed, and this builds their confidence and desire to learn more, try more and stretch themselves and their learning,” said Esben Stærk Jørgensen, president of LEGO Education. “We believe all students can gain confidence in STEAM through hands-on learning. We are excited for all FIRST LEGO League and FIRST LEGO League Jr. participants to build their confidence in learning while competing with our newest architecture-themed sets and now with the addition of our intuitive and adaptive LEGO Education SPIKE™ Prime.”
The new sets and programs for the 2019-2020 FIRST LEGO League season are based on the theme of architecture and are titled BOOMTOWN BUILD℠” and CITY SHAPER℠. The 2019-2020 FIRST LEGO League Jr. BOOMTOWN BUILD Inspire set will reach more than 130,000 children, ages 6 to 10* from 41 countries and the 2019-2020 FIRST LEGO League CITY SHAPER Challenge set, which includes a new competition mat, will reach more than 320,000 children, ages 9 to 16*, from nearly 90 countries. Students are tasked with completing a challenge designed in partnership with architects and engineers and use a variety of LEGO Education products, including LEGO Education WeDo 2.0, LEGO MINDSTORMS Education EV3 and the newly announced LEGO Education SPIKE Prime and SPIKE Prime Expansion set.
“FIRST LEGO League Jr. and FIRST LEGO League allow students to engage in the same real-world challenges that scientists and engineers face today,” said Donald E. Bossi, president of FIRST. “This coming season we’re thrilled for teams to explore city life through the architecture theme and create new, innovative solutions to improve our communities for the future. At the same time, hundreds of thousands of young students will be building problem-solving, teamwork, and communication skills that are critical to their own future success.”
To learn more about FIRST LEGO League Jr. and FIRST LEGO League, visit www.firstinspires.org.
(*ages vary by country)
About FIRST
Accomplished inventor Dean Kamen founded FIRST ® (For Inspiration and Recognition of Science and Technology) in 1989 to inspire an appreciation of science and technology in young people. Based in Manchester, N.H., FIRST designs accessible, innovative programs to build self-confidence, knowledge, and life skills while motivating young people to pursue opportunities in science, technology, and engineering. With support from over 200 of the Fortune 500 companies and more than $80 million in college scholarships, the not-for-profit organization hosts the FIRST® Robotics Competition for students in Grades 9-12; FIRST® Tech Challenge for Grades 7-12; FIRST®LEGO® League for Grades 4-8; and FIRST® LEGO® League Jr. for Grades K-4. Gracious Professionalism ® is a way of doing things that encourages high-quality work, emphasizes the value of others, and respects individuals and the community. To learn more about FIRST, go to www.firstinspires.org.
About LEGO Education
LEGO® Education offers hands-on, playful STEAM learning experiences based on the LEGO® system of bricks, hardware, software and content for students and their teachers in early learning, primary, and secondary education as well as through after-school programs and competitions. These solutions create an environment for active, collaborative learning where students build skills for their future, a lifelong love for learning and confidence in their ability to learn and solve problems, setting them up for lifelong success.
LEGO, the LEGO logo, the Minifigure and the SPIKE logo are trademarks and/or copyrights of the LEGO Group. ©2019 The LEGO Group. All rights reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190417005754/en/
Contact information
Kari Sherrodd
kari.sherrodd@lego.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom